Related Experiment Video

Updated: Aug 8, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy

E Tóthová1, M Fricova, N Stecová

  • 1Department of Hematology; Medical Faculty Hospital and UPJS, Kosice, 040 66 Slovakia. etothova@post.sk

Neoplasma
|July 5, 2002
PubMed

Insights

High bcl-2 protein expression in acute myeloblastic leukemia (AML) correlates with lower complete remission rates. Both bcl-2 and CD34 expression are independent prognostic factors for achieving remission in AML patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The bcl-2 protein plays a crucial role in apoptosis regulation.
  • Acute myeloblastic leukemia (AML) is a heterogeneous hematologic malignancy.
  • Understanding prognostic markers is vital for optimizing AML treatment strategies.

Purpose of the Study:

  • To investigate the expression of bcl-2 protein in newly diagnosed AML patients.
  • To correlate bcl-2 expression with French-American-British (FAB) subtypes and CD34 expression.
  • To assess the relationship between bcl-2 expression and clinical outcome, specifically complete remission (CR) rates.

Main Methods:

  • Flow cytometry was used to analyze bcl-2 protein expression in 67 newly diagnosed AML patients.
  • Direct immunofluorescence with an anti-bcl-2 monoclonal antibody was employed.
  • Results were correlated with FAB classification, CD34 expression, and CR rates.

Main Results:

  • Bcl-2 expression was heterogeneous, with a mean of 81% positive cells.
  • Higher bcl-2 expression percentages were observed in FAB M0 and M1 subtypes.
  • Mean fluorescence index (MFI) of bcl-2 was significantly higher in M0 and M1 compared to M4 and M5 subtypes (p=0.01).
  • Bcl-2 MFI significantly correlated with CD34 positivity and CD34 MFI.
  • High bcl-2 expression (≥20% positive cells) was associated with a lower CR rate (40.4%) compared to low expression (<20% positive cells) (72%).

Conclusions:

  • Bcl-2 protein expression is a significant factor in AML.
  • High bcl-2 MFI (>16) and CD34 expression are independent prognostic factors for achieving CR in AML.
  • These findings suggest that bcl-2 expression levels can aid in predicting treatment response in AML.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...